AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts

Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulcerative colitis data that will be out in the fourth quarter and the opportunity there. He also highlights the company's PD-1 for oncology that is commercialized by GSK.